Affiliation:
1. MedStar Health National Center for Human Factors in Healthcare
2. Patient Safety Authority
3. MedStar Health National Center for Human Factors in Healthcare and Georgetown University School of Medicine
Abstract
Intravenous (IV) vancomycin is one of the most commonly used antibiotics in U.S. hospitals. There are several complexities associated with IV vancomycin use, including the need to have an accurate patient weight for dosing, to provide close monitoring to ensure appropriate drug levels, to monitor renal function, and to continue delivery of the medication at prescribed intervals. There are numerous healthcare system factors, including workflow processes, policies, health information technology, and clinical knowledge that impact the safe use of IV vancomycin. Past literature has identified several safety hazards associated with IV vancomycin use and there are some proposed
solutions. Despite this literature, IV vancomycin–related safety issues persist. We analyzed patient safety event reports describing IV vancomycin–related issues in order to identify where in the medication process these issues were appearing, the type of medication error associated with each report, and general contributing factor themes. Our results demonstrate that recent safety reports are aligned with the issues already identified in the literature, suggesting that improvements discussed in the literature have not translated to clinical practice. Based on our analysis and current literature,
we have developed a shareable infographic to improve clinician awareness of the complications and safety hazards associated with IV vancomycin and a self-assessment tool to support identification of opportunities to improve patient safety during IV vancomycin therapy. We also recommend development of clear guidelines to optimize health information technology systems to better support safe IV vancomycin use.
Reference38 articles.
1. Center for Disease Control and Prevention. Antibiotic Use in the United States, 2017: Progress and Opportunities. US Dep Heal Hum Serv. 2017:1-40. doi:10.1073/pnas.1417106112
2. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Heal Pharm. 2009;66(1):82-98. doi:10.2146/ajhp080434
3. Matsumoto K, Takesue Y, Ohmagari N, et al. Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin: A Consensus Review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013;19(3):365-380. doi:10.1007/s10156-013-0599-4
4. Stanford Hospital & Clinics Vancomycin Dosing Guidelines 2013.; 2013. http://med.stanford.edu/content/dam/sm/bugsanddrugs/documents/dosing/2013VancomycinDosingGuide.pdf. Accessed February 6, 2020.
5. Martín-Navarro J, Petkov-Stoyanov V, Gutiérrez-Sánchez MJ. Letters to the Editor Rapid Response to High and Plasma Cells Efficacy of High Permeability Haemodialysis in Acute Renal Failure Due To. 2014:3-5. doi:10.3265/Nefrologia.pre2014.Jun.12108
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献